AU2007203233A1

AU2007203233A1 - Sublingual buccal effervescent

Info

Publication number: AU2007203233A1
Application number: AU2007203233A
Authority: AU
Inventors: Jonathan D. Eichman; John Hontz; Rajendra K. Khankari; Joseph R. Robinson; Indiran Pather Sathasivan
Original assignee: Cima Labs Inc
Current assignee: Cima Labs Inc
Priority date: 1999-03-26
Filing date: 2007-07-11
Publication date: 2007-08-02
Also published as: AU2007203233B2

Description

AUSTRALIA

Patents Act COMPLETE SPECIFICATION

(ORIGINAL)

Class Int. Class Application Number: Lodged: Complete Specification Lodged: Accepted: Published: Priority Related Art: Name of Applicant: Cima Labs Inc.

Actual Inventor(s): Sathasivan Indiran Pather, Rajendra K. Khankari, Jonathan D. Eichman, Joseph R.

Robinson, John Hontz Address for Service and Correspondence: PHILLIPS ORMONDE FITZPATRICK Patent and Trade Mark Attorneys 367 Collins Street Melbourne 3000 AUSTRALIA Invention Title: SUBLINGUAL BUCCAL EFFERVESCENT Our Ref 806607 POF Code: 1421/167086 The following statement is a full description of this invention, including the best method of performing it known to applicant(s): 1 ooq

AUSTRALIA

Patents Act COMPLETE SPECIFICATION

(ORIGINAL)

Robinson, John Hontz Address for Service and Correspondence: PHILLIPS ORMONDE FITZPATRICK Patent and Trade Mark Attorneys 367 Collins Street Melbourne 3000 AUSTRALIA Invention Title: SUBLINGUAL BUCCAL EFFERVESCENT Our Ref: 806607 POF Code: 1421/167086 The following statement is a full description of this invention, including the best method of performing it known to applicant(s): -1-

DESCRIPTION

SUBLINGUAL BUCCAL EFFERVESCENT OD The present application is a divisional application from Australian patent application number 2004242477, the entire disclosure of which is incorporated herein by reference.

TECHNICAL FIELD The present invention relates to pharmaceutical compositions, and more particularly to pharmaceutical Scompositions for oral administration of a medicament, which gcontain an effervescent agent for enhancing oral drug C absorption across the buccal, sublingual, and gingival mucosa.

SBACKGROUND ART Cq 1 0 Effervescents have been shown to be useful and advantageous for oral administration. See Pharmaceutical DosageForms: Tablets Volume I, Second Edition. A. Lieberman.

ed. 1989, Marcel Dekker, Inc. As discussed in this text, and as commonly employed, an effervescent tablet is dissolved in water to provide a carbonated or sparkling liquid drink. See also U.S. Pat. Nos. 5,102,665 and 5,468,504 to Schaeffer, herein incorporated by reference. In such a drink, the effervescent helps to mask the taste of medicaments.

Effervescent compositions have also been employed for use as taste masking agents in dosage forms which are not dissolved in water prior to administration. For example, U.S. Pat. No.

4,639,368 describes a chewing gum containing a medicament capable of absorption through the buccal cavity and containing a taste masking amount of an effervescent.

More recently effervescents have been employed to obtain rapid dissolution and/or dispersion of the medicament in the oral cavity. See U.S. Pat. Nos. 5,178,878 and 5,223,264. The effervescent tends to stimulate saliva production thereby providing additional water to aid in further effervescent action. These dosage forms give an agreeable presentation of the drug, particularly for patients who have difficulty in swallowing tablets or capsules. PCT application WO 97/06786 describes pre-gastric absorption of certain drugs using rapidly-disbursing dosage forms.

Various proposals have been advanced for oral mucosal administration of various drugs. When drugs are absorbed from the oral mucosa, they bypass the gastrointestinal and hepatic metabolism process. This can lead to a faster onset of action and/or improved O bioavailability of a drug. However, many compounds do not rapidly penetrate the oral mucosa. See, Christina Graffner, Clinical Experience with Novel Buccal and SSublinqual Administration; NOVEL DRUG DELIVERY AND ITS THERAPEUTIC 5 APPLICATION, edited by L.F. Prescott and W.S. Nimmo (1989); David Harris and Joseph R. Robinson, Drug Delivery via the Mucous Membranes of the Oral Cavity; m JOURNAL OF PHARMACEUTICAL SCIENCES, Vol. 81 (Jan. 1992); Oral Mucosal Delivery, edited by M.J. Rathbone, which are herein incorporated by reference. The compounds which may be well absorbed pre-orally (through the gastrointestinal tract) may not be well absorbed through the mucosa of the mouth because the oral mucosa O is less permeable than the intestinal mucosa and it does not offer as big a surface area as the small intestine.

Despite these and other efforts toward increasing the permeation of medicaments across the oral mucosa, there have been unmet needs for improved methods of administrating medicaments across the oral mucosa.

THE SUMMARY OF THE INVENTION The pharmaceutical compositions of the present invention comprise an orally administrable medicament in combination with an effervescent agent used as penetration enhancer to influence the permeability of the medicament across the buccal, sublingual, and gingival mucosa.

Accordingly, the present invention provides a tablet for direct oral administration of a systemically distributable pharmaceutical medicament across the oral mucosa comprising: a pharmaceutically effective amount of a medicament for oral administration across the oral mucosa, including buccal, sublingual and gingival administration; at least one pH adjusting substance in an amount to permit the relative portions of ionised and unionised forms of the medicament to be controlled; and at least one saliva activated effervescent couple present in an amount sufficient to increase absorption of said medicament across the oral mucosa; wherein said amount of said at least one effervescent couple is between 5% and 80% by weight of the tablet; X\Bre\AClanim Amemnws cdealmoc 0 said tablet suitable for buccal, sublingual and gingival administration of said _medicament across the oral mucosa.

The present invention further provides a tablet for direct oral administration of a systemically distributable pharmaceutical medicament across the oral mucosa comrisin: fentanyl: at least one pH adjusting substance in an amount to permit a therapeutically sufficient concentration of the fentanvl to be present in the unionized form: and O The present invention also provides a tablet comprising a pharmaceutically effective C amount of a medicament for oral administration across the oral mucosa, including selected from the group consisting of analgesics, sedatives, and tranquilizers, said medicament capable of buccal, sublingual and gingival administration and at least one saliva activated effervescent couple present in an amount sufficient to increase absorption of said medicament across the oral mucosa, said tablet suitable for buccal, sublingual and gingival administration of said medicament across the oral mucosa.

The present invention also provides a tablet comprising a pharmaceutically effective amount of an orally administrable, systemically distributable medicament for oral administration across the oral mucosa, including buccal, sublingual and gingival administration, at least one saliva activated effervescent couple; and at least one non-effervescent penetration enhancer, said tablet suitable for buccal, sublingual and gingival administration of said medicament across the oral mucosa.

The present invention also provides a tablet comprising prochlorperazine in an effective amount for oral administration across the oral mucosa, including buccal, sublingual and gingival administration, at least one pH adjusting substance in an amount to provide a pH sufficiently high to facilitate permeation enhancement; and (c) an effervescent couple, said tablet suitable for buccal, sublingual and gingival administration of said medicament across the oral mucosa.

The present invention also provides a tablet comprising fentanyl in an effective amount for oral administration across the oral mucosa, including buccal, sublingual and gingival administration, 2b at least one pH adjusting substance in an amount to permit a therapeutically sufficient concentration of the fentanyl to be present in the unionised form; and an _effervescent couple, said tablet suitable for buccal, sublingual and gingival Sadministration of said medicament across the oral mucosa.

The present invention also provides a method of administering at least one q systematically distributable pharmaceutical agent comprising: Na) providing a tablet including at least one effervescent agent and a pharmaceutically effective amount of an orally administrable medicament.

b) placing said tablet in the mouth of a patient so that saliva in said patients mouth activates said at lest one effervescent agent in said tablet, whereby said at least one effervescent promotes absorption of said orally administrable medicament across the oral mucosa.

The present invention also provides a method of manufacturing a solid pharmaceutical dosage form comprising combining i. A medicament in an effective amount for oral administration across the oral mucosa, including buccal, sublingual and gingival administration, and ii. at least one saliva activated effervescent couple present in an amount sufficient to increase absorption of said orally administrable medicament across the oral mucosa, in order to produce a combination; and iii. at least one pH adjusting substance in an amount additional to the amount required for effervescence; and (b)using said combination to produce said solid pharmaceutical dosage form, said solid pharmaceutical dosage form suitable for buccal, sublingual and gingival administration of said medicament across the oral mucosa.

DETAILED DESCRIPTION OF THE INVENTION One aspect of this invention is to use effervescent as penetration enhancers for influencing oral drug absorption. Effervescent agents can be used alone or in combination with other penetration enhancers, which leads to an increase in the rate and extent of absorption of an active drug. It is believed that such increase can rise from one or all of the following mechanisms: 1. reducing the mucosal layer thickness and/or viscosity; 2. tight junction alteration; WO 00/57858 PCTUS00/07567 3 3. inducing a change in the cell membrane structure; and 4. increasing the hydrophobic environment within the cellular membrane.

The present dosage forms should include an amount of an effervescent agent effective to aid in penetration of the drug across the oral mucosa. Preferably, the effervescent is provided in an amount of between about 5% and about 95% by weight, based on the weight of the finished tablet, and more Spreferably in an amount of between about 30% and about 80% by C' 10 weight. It is particularly preferred that sufficient effervescent material be provided such that the evolved gas is more than about 5cm 3 but less than about 30cm, upon exposure of the tablet to an aqueous environment. However, the amount of effervescent agent must be optimized for each specific drug.

The term "effervescent agent" includes compounds which evolve gas. The preferred effervescent agents evolve gas by means of a chemical reaction which takes place upon exposure of the effervescent agent (an effervescent couple) to water and/or to saliva in the mouth. This reaction is most often the result of the reaction of a soluble acid source and a source of carbon dioxide such as an alkaline carbonate or bicarbonate. The reaction of these two general compounds produces carbon dioxide gas upon contact with water or saliva. .Such water-activated materials must be kept in a generally anhydrous state and with little or no absorbed moisture or in a stable hydrated form, since exposure to water will prematurely disintegrate the tablet. The acid sources may be any which are safe for human consumption and may generally include food acids, acid and hydrite antacids such as, for example: citric, tartaric, amalic, fumeric, adipic, and succinics. Carbonate sources include dry solid carbonate and bicarbonate salt such as, preferably, sodium bicarbonate, sodium carbonate, potassium bicarbonate and potassium carbonate, magnesium carbonate and the like. Reactants which evolve oxygen or other gasses and which are safe for human consumption are also included.

The effervescent agent(s) of the present invention is not always based upon a reaction which forms carbon dioxide.

-WO 00/57858 PCTIUSOO/07567 4 Reactants which evolve oxygen or other gasses which are safe Sfor human consumption are also considered within the scope.

Where the effervescent agent includes two mutually reactive components, such as an acid source and a carbonate source, it is preferred that both components react completely. Therefore, an equivalent ratio of components which provides for equal equivalents is preferred. For example, if the acid used is diprotic, then either twice the amount of a mono-reactive carbonate base, or an equal amount of a di-reactive base should be used for complete neutralization to be realized. However, in other embodiments of the present invention, the amount of either acid or carbonate source may exceed the amount of the other component. This may be useful to enhance taste and/or performance of a tablet containing an overage of either component. In this case, it is acceptable that the additional amount of either component may remain unreacted.

The present dosage forms may also include in amounts additional to that required for effervescence a pH adjusting substance. For drugs that are weakly acidic or weakly basic, the pH of the aqueous environment can influence the relative concentrations of the ionized and unionized forms of the drug present in solution according to the Henderson-Hasselbach equation. The pH solutions in which an effervescent couple has dissolved is slightly acidic due to the evolution of carbon dioxide. The pH of the local environment, saliva in immediate contact with the tablet and any drug that may have dissolved from it, may be adjusted by incorporating in the tablet a pH adjusting substances which permit the relative portions of the ionized and unionized forms of the drug to be controlled. In this way, the present dosage forms can be optimized for each specific drug. If the unionized drug is known or suspected to be absorbed through the cell membrane (transcellular absorption) it would be preferable to alter the pH of the local environment (within the limits tolerable to the subject) to a level that favors the unionized form of the drug.

Conversely, if the ionized form is more readily dissolved the local environment should favor ionization.

WO 00/57858 PCT/USO/07567 I- The aqueous solubility of the drug should preferably not c-i be compromised by the effervescent and pH adjusting substance, such that the dosage forms permit a sufficient concentration of the drug to be present in the unionized form. The percentage of the pH adjusting substance and/or effervescent should ^C therefore be adjusted depending on the drug.

SSuitable pH adjusting substance for use in the present (I invention include any weak acid or weak base in amounts additional to that required for the effervescence or, Ci 10 preferably, any buffer system that is not harmful to the oral mucosa. Suitable pH adjusting substance for use in the present invention include, but are not limited to, any of the acids or bases previously mentioned as effervescent compounds, disodium hydrogen phosphate, sodium dihydrogen phosphate and the equivalent potassium salt.

The active ingredient suitable for use in the present dosage forms can include systematically distributable pharmaceutical ingredients, vitamins, minerals, dietary supplements, as well as non-systematically distributable drugs.

Preferably, the active ingredient is a systemically active pharmaceutical ingredient which is absorbable by the body through the oral mucosa. Although the dosage forms can be employed with a wide range of drugs, as discussed below, it is especially suitable for drugs and other pharmaceutical ingredients which suffer significant loss of activity in the lumen of the gastrointestinal tract or in the tissues of the gastrointestinal tract during absorption process or upon passage through the liver after absorption in the intestinal tract. Absorption through the oral mucosa allows the drug to enter the systemic circulation without first passing through the liver, and thus alleviates the loss of activity upon passage through the liver.

Pharmaceutical ingredients may include, without limitation, analgesics, anti-inflammatories, antipyretics, antibiotics, antimicrobials, laxatives, anorexics, antihistamines, antiasthmatics, antidiuretics, antiflatuents, antimigraine agents, antispasmodics, sedatives, WO 00/57858 PCT/US00/07567 antihyperactives, antihypertensives, tranquilizers, decongestants, beta blockers; peptides, proteins, oligonucleotides and other substances of biological origin, and combinations thereof. Also encompassed by the terms "active ingredient(s)", "pharmaceutical ingredient(s)" and "active agents" are the drugs and pharmaceutically active ingredients described in Mantelle, U.S. Pat. No. 5,234,957, in columns 18 through 21. That text of Mantelle is hereby incorporated by reference. Alternatively or additionally, the active ingredient can include drugs and other pharmaceutical ingredients, vitamins, minerals and dietary supplements as the same are defined in U.S. Pat. No. 5,178,878, the disclosure of which is also incorporated by reference herein.

The dosage form preferably includes an effervescent couple, in combination with the other ingredients to enhance the absorption of the pharmaceutical ingredient across the oral mucosa and to improve the disintegration profile and the organoleptic properties of the dosage form. For example, the area of contact between the dosage form and the oral mucosa, and the residence time of the dosage form in the oral cavity can be improved by including a bioadhesive polymer in this drug delivery system. See, Mechanistic Studies on Effervescent-Induced Permeability Enhancement by Jonathan Eichman (1997), which is incorporated by reference herein.

Effervescence, due to its mucus stripping, properties, would also enhance the residence time of the bioadhesive, thereby increasing the residence time for the drug absorption.

Non-limiting examples of bioadhesives used in the present invention include, for example, Carbopol 934 P, Na CMC, Methocel, Polycarbophil (Noveon AA-1), HPMC, Na alginate, Na Hyaluronate and other natural or synthetic bioadhesives.

In addition to the effervescence-producing agents, a dosage form according to the present invention may also include suitable non-effervescent disintegration agents. Non-limiting examples of non-effervescent disintegration agents include: microcrystalline, cellulose, croscarmelose sodium, WO 00/57858 PCT/US00/07567 7 crospovidone, starches, corn starch, potato starch and modified t s starches thereof, sweeteners, clays, such as bentonite, alginates, gums such as agar, guar, locust bean, karaya, pecitin and tragacanth. Disintegrants may comprise up to about 20 weight percent and preferably between about 2 and about -q of the total weight of the composition.

In addition to the particles in accordance with the present invention, the dosage forms may also include glidants, lubricants, binders, sweeteners, flavoring and coloring Ci 10 components. Any conventional sweetener or flavoring component may be used. Combinations of sweeteners, flavoring components, or sweeteners and flavoring components may likewise be used.

Examples of binders which can be used include acacia, tragacanth, gelatin, starch, cellulose materials such as methyl cellulose and sodium carboxy methyl cellulose, alginic acids and salts thereof, magnesium aluminum silicate, polyethylene glycol, guar gum, polysaccharide acids, bentonites, sugars, invert sugars and the like. Binders may be used in an amount of up to 60 weight percent and preferably about 10 to about weight percent of the total composition.

Coloring agents may include titanium dioxide, and dyes suitable for food such as those known as dyes and natural coloring agents such as grape skin extract, beet red powder, beta-carotene, annato, carmine, turmeric, paprika, etc.

The amount of coloring used may range from about 0.1 to about weight percent of the total composition.

Flavors incorporated in the composition may be chosen from synthetic flavor oils and flavoring aromatics and/or natural oils, extracts from plants, leaves, flowers, fruits and so forth and combinations thereof. These may include cinnamon oil, oil of wintergreen, peppermint oils, clove oil, bay oil, anise oil, eucalyptus, thyme oil, cedar leave oil, oil of nutmeg, oil of sage, oil of bitter almonds and cassia oil.

Also useful as flavors are vanilla, citrus oil, including lemon, orange, grape, lime and grapefruit, and fruit essences, including apple, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot and so forth. Flavors which have been SWO 00/57858 PCTUS00/07567 8 found to be particularly useful include commercially available orange, grape, cherry and bubble gum flavors and mixtures thereof. The amount of flavoring may depend on a number of factors, including the organoleptic effect desired. Flavors m 5 may be present in an amount ranging from about 0.05 to about 3 C percent by weight based upon the weight of the composition.

g Particularly preferred flavors are the grape and cherry flavors C and citrus flavors such as orange.

One aspect of the invention provides a solid, oral tablet Cq 10 dosage form suitable for sublingual, buccal, and gingival administration. Excipient fillers can be used to facilitate tableting. The filler desirably will also assist in the rapid dissolution of the dosage form in the mouth. Non-limiting examples of suitable fillers include: mannitol, dextrose, lactose, sucrose, and calcium carbonate.

METHOD OF MANUFACTURE Tablets can either be manufactured by direct compression, wet granulation or any other tablet manufacturing technique.

See, U.S. Pat. Nos. 5,178,878 and 5,223,264, which are incorporated by reference herein. The tablet may be a layered tablet consisting of a layer of the active ingredient sandwiched between a bioadhesive layer and an effervescence layer. Other layered forms which include the ingredients set forth above in layers of diverse compositions.

Effervescence Level: Between 5% Tablet size: Between 3/16" 5/8" Tablet hardness: Between 5N and Route of administration: Sublingual, Buccal, Gingival The dosage form may be administered to a human or other mammalian subject by placing the dosage form in the subject's mouth and holding it in the mouth, either adjacent a cheek (for buccal administration), beneath the tongue (for sublingual administration) and between the upper lip and gum (for gingival administration). The dosage form spontaneously begins to disintegrate due to the moisture in the mouth. The disintegration, and particularly the effervescence, stimulates additional salivation which further enhances disintegration.

WO 00/57858 PCT/US00/07567 EXAMPLE 1 The dosage form should include Fentanyl, an effervescent and pH adjusting substance so that the pH is adjusted to neutral (or slightly higher) since the pKa of fentanyl is 7.3.

At this pH, the aqueous solubility of this poorly water-soluble drug would not be compromised unduly, and would permit a Ssufficient concentration of the drug to be present in the unionized form.

Two fentanyl formulations, each containing 36% C- 10 effervescence were produced. These tablets were compressed using half-inch shallow concave punches.

WO 00/57858 PCTIUSOO/07567 FORMULATION COMPONENT

QUANTITY

(MG)

SHORT Fentanyl, citrate, USP 1.57 DISINTEGRATION Lactose monohydrate 119.47 TIME Microcrystalline 119.47 Cellulose, Silicified Sodium carbonate, 46.99 anhydrous Sodium bicarbonate 105 Citric acid, anhydrous Polyvinylphrrolidone, cross-linked Magnesium stearate Col loidal silicon dioxide Total tablet mass Soo LOGFentanyl citrate, USP 1.57 DISINTEGRATION Lactose monohydrate 270.93 T3ESodium carbonate, 40.00 anhydrous Sodium bicarbonate 105 Citric acid, anhydrous Magnesium stearate colloidal silicon dioxide Total tablet mass Soo WO 00/57858 PCT/US00/07567 EXAMPLE 2 The dosage form included prochlorperazine (pKa=8.1), an effervescent and pH adjusting substance so that a slightly higher pH is produced to facilitate the permeation enhancement.

With respect to prochlorperazine, an anti-emetic drug, two formulations, buccal and sublingual, were developed. The buccal tablets were compressed as quarter inch diameter biconvex tablets, whereas the sublingual tablets were three-eighths inch diameter biconvex tablets. These dimensions were chosen to give a comfortable fit in the respective part of the oral cavity for which they were designed. The formulae for these tablets are as follows: FORMULATION COMPONENT NAME QUANTITY

(MG)

BUCCAL Prochlorperazine 5.00 Sodium Bicarbonate 15.52 Citric Acid, Anhydrous 11.08 Sodium Bicarbonate 45.78 HPMC K4M Prem 5.00 Dicalcium phosphate 5.00 dihydrate Mannitol 11.67 Magnesium Stearate 0.95 Total 100.00 SUBLINGUAL Prochlorperazine 5.00 Sodium Bicarbonate 61.25 Citric Acid, Anhydrous 43.75 Sodium Bicarbonate Sodium carbonate 91.25 WO 00/57858 PCT/USOO/07567 12 HPMC Methocel K4M Prem Mannitol Magnesium Stearate 3.75~ Total 400 01 INDUSTRIAL APPLICABTLITY C-i The invention relates to the pharmaceutical and medical industries and to the production of dosage forms.

Throughout the description and the claims of this specification the word "comprise" and variations of the word, such as "comprising" and "comprises" is not intended to exclude other additives, components, integers or steps.

The discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention.

It is not suggested or represented that any or all of these matters formed part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed in Australia before the priority date of each claim of this application.

Claims

2. The tablet of claim 1, wherein said effervescent couple is present in an amount of between 20% and 80% by weight.
3. The tablet of claim 2, wherein said effervescent couple is present in an amount of between 30% and 80% by weight.
4. The tablet of claim 1, further comprising a non-effervescent penetration enhancer. The tablet of claim 1, further comprising a bioadhesive.
6. The tablet of claim 1, further comprising a non-effervescent disintegration agent.
7. The tablet of claim 1, further comprising at least one glidant, lubricant, binder, sweetener, flavorant or coloring component.
8. The tablet of claim 1, wherein said medicament is selected from the group consisting of analgesics, anti-inflammatories, antipyretics, antibiotics, antimicrobials, laxatives, anorectics, antihistamines, antiasthmatics, X\BrmeelAI~ClbA n Amenemen deadoc 14 0 antidiuretics, antiflatulents, antiemetics, antimigraine agents, antispasmodics, C sedatives, antihyperactives, antihypertensives, tranquilizers, decongestants, and beta blockers.
9. The tablet of claim 1, wherein said at least one pH-adjusting substance is present in an amount which is sufficient to change the pH of local environment Sof said medicament at a site of absorption in the mouth. The tablet of claim 9, wherein said at least one pH-adjusting substance is present in an amount which is sufficient to change the pH of a local O environment of said medicament at a site of absorption in the mouth to favor an unionised form of said medicament.
11. The tablet of claim 9, wherein said at least one pH-adjusting substance is present in an amount which is sufficient to change the pH of a local environment of said medicament at a site of absorption in the mouth to favor an ionised form of said medicament.
12. The tablet of claim 1, which is adapted for gingival administration.
13. The tablet of claim 1, which is adapted for sublingual administration.
14. The tablet of claim 1, wherein said effervescent couple includes a base selected from the group consisting of sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate and magnesium carbonate, and an acid selected from the group consisting of citric acid, tartaric acid, malic acid, fumaric acid and adipic acid. The tablet of claim 1, wherein said medicament is prochlorperazine and said pH adjusting substance is present in.an amount to provide a pH sufficiently high to facilitate permeation enhancement.
16. A tablet comprising: a pharmaceutically effective amount of an orally administrable, systemically distributable medicament for oral administration across the oral mucosa, including buccal, sublingual and gingival administration; at least one saliva activated effervescent couple; and XVrM"uW'Jum AmmWamwn demvdoc at least one non-effervescent penetration enhancer; Ssaid tablet suitable for buccal, sublingual and gingival administration of said Z medicament across the oral mucosa.
17. The tablet of claim 16, further comprising at least one pH-adjusting substance.
18. The tablet of claim 16, wherein the amount of said at least one effervescent Scouple is 5% to 95% by weight of the tablet.
19. The tablet of claim 17, wherein said at least one pH-adjusting substance is C present in an amount which is sufficient to change the pH of a local environment of said medicament at a site of absorption in the mouth. The tablet of claim 17 wherein said medicament is capable of existing in ionised form and unionised form in the mouth.
21. The tablet of claim 20, wherein the amount of said pH-adjusting substance is sufficient to favor said unionised form of said medicament.
22. The tablet of claim 20, wherein the amount of said pH-adjusting substance is sufficient to favor said ionised form of said medicament.
23. A tablet comprising: a pharmaceu icaly .effective amount of a medicament for oral administration across the oral mucosa, including selected from the group consisting of analgesics, sedatives, and tranquilizers, said medicament capable of buccal, sublingual and gingival administration; and at least one saliva activated effervescent couple present in an amount sufficient to increase absorption of said medicament across the oral mucosa; said tablet suitable for buccal, sublingual and gingival administration of said medicament across the oral mucosa.
24. A tablet according to claim 23 wherein said oral mucosa is selected from the buccal, sublingual and gingival mucosa. X:\BrBBWetCWam Amesndmet dandoc A tablet according to claims 23 or 24 wherein said amount of said at least one C effervescent couple is between 5% and 95% by weight of the tablet.
26. A tablet according to claims 23 to 25 further comprising at least one pH adjusting substance in an amount to permit the relative portions of ionised and unionised forms of the medicament to be controlled. m 27. A tablet according to claim 26 wherein said pH adjusting substance is a weak c acid or a weak base in an amount additional to that required for effervescence, or a buffer system not harmful to the oral mucosa.
28. A tablet according to claims 26 or 27, wherein said base is selected from the group consisting of sodium carbonate, potassium carbonate, magnesium carbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, sodium bicarbonate and potassium bicarbonate.
29. A tablet according to claims 26 to 28 wherein said at least one pH-adjusting substance is present in an amount which is sufficient to change the pH of a local environment of said medicament at a site of absorption in the mouth to favor an ionised form of said medicament. A tablet according to claims 26 to 28 wherein said at least one pH-adjusting substance is present in an amount which is sufficient to change the pH of a local environment of said medicament at a site of absorption in the m6uth to favor an ionised form of said medicament.
31. A tablet according to claims 23 or 30 wherein said medicament is an analgesic or a sedative.
32. A tablet according to claims 23 to 30 further comprising at least one member selected from the group consisting of glidants, lubricants, binders, sweeteners, flavorants, colorants, non-effervescent disintegration agents, bioadhesives, and non-effervescent penetration enhancers. X:\Bmrea\Clalm Amefment deaOdoc 1- 17
33. A tablet according to claims 23 to 32 wherein said effervescent couple is ri present in an amount of between 5% to 80%; or 20% to 80% by weight; Z altematively, 30% to 80% be weight.
34. A tablet according to claims 23 to 33 wherein said effervescent couple includes a base selected from the group consisting of sodium bicarbonate, sodium Scarbonate, potassium bicarbonate, potassium carbonate and magnesium Scarbonate, and an acid selected from the group consisting of citric acid, tartaric N acid, malic acid, fumaric acid and adipic acid. A tablet comprising: prochlorperazine in an effective amount for oral administration across the oral mucosa, including buccal, sublingual and gingival administration; at least one pH adjusting substance in an amount to provide a pH sufficiently high to facilitate permeation enhancement; and; an effervescent couple; said tablet suitable for buccal, sublingual and gingival administration of said medicament across the oral mucosa.
36. A tablet comprising: fentanyl in an effective amount for oral administration across the oral mucosa, including buccal, sublingual and gingival administration; at least one pH adjusting substance in an amount to permit a therapeutically sufficient concentration of the fentanyl to be present in the unionised form; and an effervescent couple; said tablet suitable for buccal, sublingual and gingival administration of said medicament across the oral mucosa.
37. The tablet of claim 36 wherein said effervescent couple is present in an amount sufficient to increase absorption of said medicament across the oral mucosa.
38. The tablet of claim 36, wherein said effervescent couple is present in an amount of 36% by weight.
39. A method of manufacturing a solid pharmaceutical dosage form comprising XBrMAUexDcIam Amendmert deandoc Combining i. A medicament in an effective amount for oral administration across the oral mucosa, including buccal, sublingual and gingival administration, and ii. At least one saliva activated effervescent couple present in an amount sufficient to increase absorption of said orally administrable medicament across the oral mucosa, in order to produce a combination; and iii. at least one pH adjusting substance in an amount additional to the amount required for effervescence; and Using said combination to produce said solid pharmaceutical dosage form; Said solid pharmaceutical dosage form suitable for buccal, sublingual and gingival administration of said medicament across the oral mucosa. The method of claim 39, wherein said solid pharmaceutical dosage further comprises at least one bioadhesive.
41. The method of claim 39, wherein said solid pharmaceutical dosage further comprises a non-effervescent disintegration agent.
42. The method of claim 39, wherein said solid pharmaceutical dosage further comprises one or more glidants, lubricants, binders, sweeteners, flavourants and colorant component.
43. The method of claim 39, wherein said orally administrable medicament is selected from the group consisting of analgesics, anti-inflammatories, antipyretics, antibiotics, antimicrobials, laxatives, anorectics, antihistamines, antiasthmatics, antidiuretics, antiflatulents, antiemeties, antimigraine agents, antispasmodics, sedatives, antihyperactives, antihypertensives, tranquilizers, decongestants, and beta blockers.
44. The method of claim 39, wherein said at least one saliva activated effervescent couple is present in an amount of between 5% by weight to 95% by weight. The method of claim 44, wherein said at least one saliva activated effervescent couple is present in an amount of between 5% by weight to 80% by weight. X1BreAWaClaitm Amatedmenrts dea.do t. 19 0 46. The method of claim 39, wherein said at least one saliva activated effervescent N couple is present in an amount of between 20% and 80% by weight.
47. The method of claim 46, wherein said at least one effervescent couple is present in an amount of between 30% and 80% by weight.
48. The method according to claim 39, wherein said at least one effervescent C,-I Scouple is present in an amount sufficient to evolve a gas in an amount between C 5cm 3 to 30cm 3 c 49. The method of claim 39, wherein said amount of said at least one pH adjusting substance is tolerable to the subject and wherein said pH adjusting substance and said amount thereof are selected to alter pH of a local environment of said medicament to control the relative concentrations of ionised and unionised forms of said medicament. The method according to claim 49, wherein said pH adjusting substance and said amount thereof are selected to favor the ionised form of said medicament.
51. The method according to claim 50, wherein said pH adjusting substance and said amount thereof are selected to favor the unionised form for said medicament.
52. The method according to claim 49, wherein said pH adjusting substance is a base.
53. The method according to claim 52, wherein said base is selected from the group consisting of sodium carbonate, potassium carbonate, magnesium, carbonate, disodium hydrogen phosphate, sodium dihydrogen phosphate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, sodium bicarbonate and potassium bicarbonate.
54. The method of claim 39, wherein said solid pharmaceutical dosage further comprises a non-effervescent penetration enhancer. The method of claim 39, wherein said solid pharmaceutical dosage form is a layered tablet. X.&BrsWa~A~C n A n Aerm deandoc -1 o
56. The tablet according to any one of claims 1, 16, 23, 35 and 36, substantially as hereinbefore described with reference to any of the Examples.
57. The method of claim 39, substantially as hereinbefore described with reference to any of the Examples. (N- mC 0C